This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Yondelis
  • /
  • A Study of Trabectedin or Dacarbazine for the Trea...
Clinical trial

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Read time: 1 mins
Last updated:1st Jun 2011

The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma
Enrollment: 579
Study Start Date: June 2011
Estimated Study Completion Date: January 2016
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Trabectedin
- Active Comparator: Dacarbazine

Category Value
Study start date 2011-06-01

View full details